Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Major Breakout is in the making
Get in now or miss the big opportunity ..gl
Buy Confirmed by AmericanBulls
http://americanbulls.com/StockPage.asp?CompanyTicker=EDAP&MarketTicker=NASD&TYP=S
Patience pays off. The market wavered a bit but finally confirmed the recent bullish formation. The dose of the previous day was not enough for a BUY-IF confirmation but today it is. The market opened with a gap up and the day’s activity resulted in a close higher than the open. This is a valid confirmation criterion. The market is now ready for a bullish move.
Still very very cheap here .. Our day like OREX is coming very soon
MM has shaking the tree again bawaha
Those who lost their cheap shares must pay more now bawahaha
This stock is a gift below $4 .Payday like OREX today coming guys
GREAT BUYING OPPORTUNITY FOLKS
Although HIFU is a relatively new procedure for prostate cancer treatment, it represents what may become the next generation of minimally invasive therapy for prostate cancer. While clinical experience with HIFU is still limited, the technology has been extensively studied and developed to the point that I personally believe that it is indeed ready for prime time. The control and precision that HIFU provides truly allows the surgeon to precisely ablate the prostate gland with pinpoint accuracy and thereby preserve the adjacent structures. Furthermore, because HIFU is non-ionizing, there is no collateral tissue damage. Despite not being FDA-approved in the U.S., HIFU remains my first choice for therapy in radiation failure, focal therapy, and potency sparing surgery. For all other cases, it is my relative first choice depending on my patients’ desire.
The development of obstruction and possibly sloughing is the most common side effect of HIFU. Many European centers are performing prostate incisions or TURPs prior to HIFU in an attempt to alleviate this problem. I anticipate changes in the technique and perhaps new developments in equipment that may resolve this issue. Improvements in technology will more easily allow the surgeon to fit all of the currently rectangular treatment box into the elliptical shape of the prostate. This will undoubtedly improve our ability to totally ablate the entire prostate gland.
Of course, longer term follow-up and clinical experience is required, and as with any therapy, not everyone is going to have a local cure. However, in my opionion, HIFU should be seriously considered in the primary treatment of prostate cancer, and I feel it should be the first choice for radiation failure cases.
More news is on the way to push this baby to the moon
Good News out today .
The uptrend will continue
I think a Major breakout is in the making
EDAP is still very very cheap
Edap will hit new 52W this week .
EDAP is definitely wayy oversold i think rebound will start today ..
with approval around the corner ,you will never see this low again .
good call fxcm
Great buying opportunity at this level
Major breakout in the making ...
MM trying all they can to keep it down ,they want more cheap shares before the real rally coming .
This low float Stock will explode into Double Digits with FDA approval .Please do your own research and realise the great Potential .GLTA !!!
Market Cap : 45 Million$
Cash : 15,8 Million$
Price : 4 $
Shares Out : 11,1 M
Press Release Source: EDAP TMS SA On Thursday August 19, 2010, 9:15 am EDT
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We are actively moving forward in obtaining approval in major lithotripsy markets for our recently developed, innovative Sonolith i-move lithotripter. Our recent 510(k) application to the FDA is a clear milestone for EDAP's expansion in this field. In addition to our high-range fully integrated Sonolith I-sys lithotripter that received 510(k) marketing clearance a year ago, our compact multi-configurations Sonolith i-move device offers a wide range of urinary stones treatment options to mid-size clinics and hospitals, hence covering all lithotripsy market segments. We look forward to working with the FDA in view of approval of our Sonolith i-move, hence providing U.S. patients and physicians with the most versatile advanced treatment option."
510(k) Status Program
Submitters may request information on their 510(k) review status 90 days after the initial log-in date of the 510(k).
What a bargain
In 1-2 years this stock will be over 30 dollar
consolidation is over now watch for new highs coming
Market cap of 45 million is a joke
Great buying opportunity . FDA approval could come any time now .
EDAP will hit all time high within minutes with approval .
Edap =the best stock to own on this time
Approval coming very soon = 10 dollar +++ around the corner
I thin FDA news coming next week .
Edap will explode like dndn or hgsi with such low float
The offering ($1,50 per Share) creates a great buying Opportunity .Now we know that Urocidin definitely works in Bladder Cancer means this is the next Blockbuster . Market-cap of 125 million$ is wayyy undervalued .Offering will be complete in mid December and the Rally will continue .This Stock is still under Radar .
This is a once in a lifetime Opportunity .
Upcoming Milestones:
Start of the Global Phase 3 Study in 2010 << trigger a Milestone payment from Endo
Econiche approval in early 2011 (jan or feb) << Major share price driver
INVESTMENT HIGHLIGHTS
• With the recent positive results from Urocidin™’s bladder cancer Phase III
trial, Bioniche’s co-developer, Endo, has committed to invest considerable
financial and other corporate resources to an expanded bladder
cancer programme.
• Endo will commence a large, multi-country, multi-centre additional
clinical trial in refractory patients to gain registration of Urocidinâ„¢ in
the USA and Canada.
• Urocidin™ is expected to address a material unmet need in the treatment
of bladder cancer where the current standard of care, BCG, dates
back over 30 years and, the Company believes, has issues with respect
to its efficacy, safety and tolerability.
• Bioniche has invested more than 10 years and approximately C$130 million
in bringing the Urocidinâ„¢ technology to its current stage.
• The Animal Health division provides the Company with ongoing cash
flow and is a world market leader in a number of its product offerings.
• With full licensing approval in Canada, the Food Safety division has
developed the world’s first fully licensed cattle vaccine designed to
reduce the E. coli O157 infection rates in humans resulting from consumption
of contaminated beef products, as well as infections related
to exposure to contaminated water and produce.
• The Company is currently investing in the development of other food
safety vaccines including a vaccine to prevent Salmonella in swine,
cattle and chickens.
The offering ($1,50 per Share) creates a great buying Opportunity .Now we know that Urocidin definitely works in Bladder Cancer means this is the next Blockbuster . Market-cap of 125 million$ is wayyy undervalued .Offering will be complete in mid December and the Rally will continue .This Stock is still under Radar .
This is a once in a Lifetime Opportunity .
Upcoming Milestones:
Start of the Global Phase 3 Study in 2010 << trigger a Milestone payment from Endo
Econiche approval in early 2011 (jan or feb) << Major share price driver
INVESTMENT HIGHLIGHTS
• With the recent positive results from Urocidin™’s bladder cancer Phase III
trial, Bioniche’s co-developer, Endo, has committed to invest considerable
financial and other corporate resources to an expanded bladder
cancer programme.
• Endo will commence a large, multi-country, multi-centre additional
clinical trial in refractory patients to gain registration of Urocidinâ„¢ in
the USA and Canada.
• Urocidin™ is expected to address a material unmet need in the treatment
of bladder cancer where the current standard of care, BCG, dates
back over 30 years and, the Company believes, has issues with respect
to its efficacy, safety and tolerability.
• Bioniche has invested more than 10 years and approximately C$130 million
in bringing the Urocidinâ„¢ technology to its current stage.
• The Animal Health division provides the Company with ongoing cash
flow and is a world market leader in a number of its product offerings.
• With full licensing approval in Canada, the Food Safety division has
developed the world’s first fully licensed cattle vaccine designed to
reduce the E. coli O157 infection rates in humans resulting from consumption
of contaminated beef products, as well as infections related
to exposure to contaminated water and produce.
• The Company is currently investing in the development of other food
safety vaccines including a vaccine to prevent Salmonella in swine,
cattle and chickens.
Load up before the Institutions coming .The most of them will start buying at $5+ .
Approval is around the corner .Mcap of 50 million is a joke and this a once in a lifetime opportunity .
Approval is coming
edap is still massive undervalued .
close in the green ????
looks good
Consolidation is a great opportunity to load up the truck before the FDA news is out .
This stock will explode to 10$+ in no time easily
We could see 5$+ today
EDAP is still very very cheap with a mcap of 50 M .
EDAP WILL HIT NEW HIGH TODAY
CHART LOOKS SUPER STRONG BULLISH
Edap is back on track to hit new highs .
Best time to load up cheap shares before the monster jump coming
Marketcap of 45 M makes me a laugh . 10$ ++ coming with such low float
LAST CHANCE TO BUY EDAP BELOW 5$
MARKET CAP OF 48 M IS STILL RIDICULOUS FOR SUCH BIG POTENTIAL
PHASE 3 SUCCESS IN BLADDER CANCER YIPPIIIIIIIIII
PHASE 3 SUCCESS FOR BIONICHE (BNC.TO) .LOAD UP THE TRUCK WE HAVE A HUGE WINNER HERE .MARKET CAP OF 120 MIL$ IS RIDICULOUS .
BNC.TO WILL BE THE NEXT BIG CASH COW .
http://finance.yahoo.com/news/UrocidinTM-Phase-III-Trial-prnews-3143154188.html?x=0&.v=11
Urocidin(TM) Phase III Trial Results Trigger Milestone Payment to Bioniche from Endo
The current milestone payment was triggered by Urocidinâ„¢ attaining a contractual efficacy goal from an ongoing U.S. Food and Drug Administration (FDA) Phase III registration trial. Urocidinâ„¢ is a product for non-muscle-invasive bladder cancer that is refractory to current first-line therapy. The clinical trial providing results was initiated in late 2006, prior to the execution of the agreement between the parties.
PHASE 3 SUCCESS IN BLADDER CANCER YIPPIIIIII
PHASE 3 SUCCESS FOR BIONICHE (BNC.TO) .LOAD UP THE TRUCK WE HAVE A HUGE WINNER HERE .MARKET CAP OF 120 MIL$ IS RIDICULOUS .
BNC.TO WILL BE THE NEXT BIG CASH COW .
http://finance.yahoo.com/news/UrocidinTM-Phase-III-Trial-prnews-3143154188.html?x=0&.v=11
Urocidin(TM) Phase III Trial Results Trigger Milestone Payment to Bioniche from Endo
The current milestone payment was triggered by Urocidinâ„¢ attaining a contractual efficacy goal from an ongoing U.S. Food and Drug Administration (FDA) Phase III registration trial. Urocidinâ„¢ is a product for non-muscle-invasive bladder cancer that is refractory to current first-line therapy. The clinical trial providing results was initiated in late 2006, prior to the execution of the agreement between the parties.
LAST CHANCE TO BUY BELOW 5 DOLLAR
THE INSTITUTION WILL START BUYING TOO AT $5 +.
RALLLYYYYYY EDAP RALLLYYYY
FDA APPROVAL IS AROUND THE CORNER . MARKET CAP OF 40 MILLION$ IS STILL RIDICULOUS .
FDA approval is coming .EDAP is still very very cheap
Double digits is on the way
4 dollar today ???
EDAP will definitely hit 6$+ next week .
BOOOOOOOOOOOOOOOM
BUY NOW OR MISS THE MONSTER OPPORTUNITY .
MONEY MONEY MONEY
STRONG BUY SIGNALS ..100% BUY
http://www.barchart.com/opinions/stocks/EDAP
Market-Cap of 33 Million US$ is RIDICULOUS .EDAP will be into Double-Digits very soon .This stock will move like HGSI or DNDN .
Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study
EDAP Reports Publication of Long-Term Clinical Results for Largest Cohort of Ablatherm-HIFU Patients
Favorable Clinical Outcomes for Prostate Cancer Patients Treated Over 15 Years
Press Release Source: EDAP TMS SA On Wednesday September 8, 2010, 9:46 am EDT
LYON, France, Sept. 8, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP - News), the global leader in therapeutic ultrasound, today reported favorable clinical outcomes for patients treated with Ablatherm-HIFU. A total of 803 patients with localized prostate cancer, treated with Ablatherm-HIFU from 1993 until 2007, were reported in a study carried out by Dr. Sebastien Crouzet, Urologist at Edouard Herriot Hospital, Lyon, France. The analysis has been published electronically by the medical journal European Urology, the official scientific publication of the European Association of Urology, and will appear in an upcoming print edition of European Urology. These results were recently presented by Dr. Crouzet at the World Congress of Endourology in Chicago.
This French multi-centric study reports the largest series of patients who have been followed for the longest amount of time. The durability of efficacy outcomes of robotic Ablatherm-HIFU in the treatment of localized prostate cancer is now established out to eight years. Clinical results obtained using Ablatherm-HIFU were favorable. For a representative number of patients with a minimum of two year follow-up and a maximum of 15 years, the cancer specific survival rate and the freedom from metastatic disease rate were 99% and 97%, respectively, at eight years. In this study, the local control of the disease was achieved with an 85% rate of negative biopsies and a biochemical disease free survival rate (Phoenix criteria) of 83% in low risk cancer patients.
These results build upon those already published in 2006 from a cohort of 297 patients treated with Ablatherm-HIFU at Edouard Herriot Hospital in Lyon, France. The data clearly demonstrates efficacy and stability of Ablatherm-HIFU approach in the treatment of localized prostate cancer.
Dr. Sebastien Crouzet commented, "Ablatherm-HIFU long term results compiled in this study were very positive in terms of efficacy. The clinical outcomes clearly demonstrate stability and efficacy over time using this robotic non-operator dependant approach. Based on these positive findings, Ablatherm-HIFU should be offered to a younger and wider patient population suffering from localized prostate cancer, as it would preserve their quality of life by avoiding risk, such as incontinence and impotence."
Marc Oczachowski, EDAP's Chief Executive Officer, added, "This publication demonstrating Ablatherm-HIFU efficacy and great stability over a long term period represents a major milestone in the HIFU acceptance process as it further validates Ablatherm-HIFU role as a standard of care for the treatment of localized prostate cancer. This further validation will be a key element in helping EDAP market HIFU, create awareness among patients, drive adoption among the clinical community and increase recognition by healthcare authorities."
Last chance to buy at this low
FDA action within the next 2 weeks .
RALLLLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
THIS STOCK IS STILL WAYYYYYYY UNDERVALUED .THE BEST BUY OPPORTUNITY OUT THERE
APPROVAL IS COMING VERY SOON
LOAD UP THE TRUCK WILE ITS VERY CHEAP